156 related articles for article (PubMed ID: 27013655)
61. Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review.
Yu L; Li K; Zhang X
Oncotarget; 2017 Dec; 8(70):115774-115786. PubMed ID: 29383200
[TBL] [Abstract][Full Text] [Related]
62. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.
Roś-Mazurczyk M; Wojakowska A; Marczak Ł; Polański K; Pietrowska M; Polanska J; Dziadziuszko R; Jassem J; Rzyman W; Widlak P
Acta Biochim Pol; 2017; 64(3):513-518. PubMed ID: 28803255
[TBL] [Abstract][Full Text] [Related]
63. The prowess of metabolomics in cancer research: current trends, challenges and future perspectives.
Taunk K; Jajula S; Bhavsar PP; Choudhari M; Bhanuse S; Tamhankar A; Naiya T; Kalita B; Rapole S
Mol Cell Biochem; 2024 May; ():. PubMed ID: 38814423
[TBL] [Abstract][Full Text] [Related]
64. Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.
Xu Y; Ding K; Peng Z; Ding L; Li H; Fan Y
Mol Cancer Ther; 2024 May; 23(5):733-742. PubMed ID: 38346938
[TBL] [Abstract][Full Text] [Related]
65. The neonatal blood spot metabolome in retinoblastoma.
Yan Q; He D; Walker DI; Uppal K; Wang X; Orimoloye HT; Jones DP; Ritz BR; Heck JE
EJC Paediatr Oncol; 2023 Dec; 2():. PubMed ID: 38130370
[TBL] [Abstract][Full Text] [Related]
66. Pilot study of plasma creatine riboside as a potential biomarker for cervical cancer.
Oike T; Osu N; Yoshimoto Y; Obinata H; Yoshikawa K; Harris CC; Ohno T
Heliyon; 2023 Jun; 9(6):e16684. PubMed ID: 37292314
[TBL] [Abstract][Full Text] [Related]
67. Metabolic biomarkers in lung cancer screening and early diagnosis (Review).
Xu Y; Dong X; Qin C; Wang F; Cao W; Li J; Yu Y; Zhao L; Tan F; Chen W; Li N; He J
Oncol Lett; 2023 Jun; 25(6):265. PubMed ID: 37216157
[TBL] [Abstract][Full Text] [Related]
68. What Can Current Biomarker Data Tell Us About the Risks of Lung Cancer Posed by Heated Tobacco Products?
Braznell S; Campbell J; Gilmore AB
Nicotine Tob Res; 2024 Feb; 26(3):270-280. PubMed ID: 37210693
[TBL] [Abstract][Full Text] [Related]
69. Metabolomic investigation of urinary extracellular vesicles for early detection and screening of lung cancer.
Yang Q; Luo J; Xu H; Huang L; Zhu X; Li H; Yang R; Peng B; Sun D; Zhu Q; Liu F
J Nanobiotechnology; 2023 May; 21(1):153. PubMed ID: 37189121
[TBL] [Abstract][Full Text] [Related]
70. A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US.
James BA; Williams JL; Nemesure B
Front Genet; 2023; 14():1141058. PubMed ID: 37082203
[No Abstract] [Full Text] [Related]
71. Non-Invasive Biomarkers for Early Lung Cancer Detection.
Saman H; Raza A; Patil K; Uddin S; Crnogorac-Jurcevic T
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497263
[TBL] [Abstract][Full Text] [Related]
72. Lung cancer susceptibility beyond smoking history: opportunities and challenges.
Hanash S
Transl Lung Cancer Res; 2022 Jul; 11(7):1230-1232. PubMed ID: 35958329
[No Abstract] [Full Text] [Related]
73. Creatine riboside is a cancer cell-derived metabolite associated with arginine auxotrophy.
Parker AL; Toulabi L; Oike T; Kanke Y; Patel D; Tada T; Taylor S; Beck JA; Bowman E; Reyzer ML; Butcher D; Kuhn S; Pauly GT; Krausz KW; Gonzalez FJ; Hussain SP; Ambs S; Ryan BM; Wang XW; Harris CC
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35838048
[TBL] [Abstract][Full Text] [Related]
74. Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer.
Yan X; Liu C
Front Surg; 2022; 9():865040. PubMed ID: 35651679
[TBL] [Abstract][Full Text] [Related]
75. Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis.
Jacyna J; Kordalewska M; Artymowicz M; Markuszewski M; Matuszewski M; Markuszewski MJ
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267519
[TBL] [Abstract][Full Text] [Related]
76. Metabolomic Profiling in Lung Cancer: A Systematic Review.
Madama D; Martins R; Pires AS; Botelho MF; Alves MG; Abrantes AM; Cordeiro CR
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564447
[TBL] [Abstract][Full Text] [Related]
77. Metabolic Changes in Early-Stage Non-Small Cell Lung Cancer Patients after Surgical Resection.
Ahmed N; Kidane B; Wang L; Nugent Z; Moldovan N; McElrea A; Shariati-Ievari S; Qing G; Tan L; Buduhan G; Srinathan SK; Aliani M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208545
[TBL] [Abstract][Full Text] [Related]
78. Metabolomic Laboratory-Developed Tests: Current Status and Perspectives.
Lichtenberg S; Trifonova OP; Maslov DL; Balashova EE; Lokhov PG
Metabolites; 2021 Jun; 11(7):. PubMed ID: 34206934
[TBL] [Abstract][Full Text] [Related]
79. Urinary Biomarkers for Early Diagnosis of Lung Cancer.
Gasparri R; Sedda G; Caminiti V; Maisonneuve P; Prisciandaro E; Spaggiari L
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33923502
[TBL] [Abstract][Full Text] [Related]
80. Solid phase microextraction chemical biopsy tool for monitoring of doxorubicin residue during in vivo lung chemo-perfusion.
Bojko B; Looby N; Olkowicz M; Roszkowska A; Kupcewicz B; Reck Dos Santos P; Ramadan K; Keshavjee S; Waddell TK; Gómez-Ríos G; Tascon M; Goryński K; Cypel M; Pawliszyn J
J Pharm Anal; 2021 Feb; 11(1):37-47. PubMed ID: 33717610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
